Mankind Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE634S01028
  • NSEID: MANKIND
  • BSEID: 543904
INR
2,469.60
-106.3 (-4.13%)
BSENSE

Jul 31, 03:30 PM

BSE+NSE Vol: 24.74 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Zydus Lifesci.
Lupin
Laurus Labs
Mankind Pharma
Divi's Lab.
Biocon
Torrent Pharma
Aurobindo Pharma
Cipla
Alkem Lab
Dr Reddy's Labs

Why is Mankind Pharma Ltd ?

1
High Management Efficiency with a high ROCE of 20.79%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.74 times
3
Healthy long term growth as Operating profit has grown by an annual rate 20.15%
4
Positive results in Jun 26
  • OPERATING CF(Y) Highest at Rs 2,751.99 Cr
  • OPERATING PROFIT TO INTEREST(Q) Highest at 9.60 times
  • PAT(Latest six months) At Rs 1,142.07 cr has Grown at 32.38%
5
High Institutional Holdings at 24.84%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Mankind Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Mankind Pharma for you?

Medium Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Mankind Pharma
-3.8%
-0.15
25.33%
Sensex
-3.81%
-0.28
13.58%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
17.73%
EBIT Growth (5y)
20.15%
EBIT to Interest (avg)
29.20
Debt to EBITDA (avg)
1.33
Net Debt to Equity (avg)
0.26
Sales to Capital Employed (avg)
0.79
Tax Ratio
19.29%
Dividend Payout Ratio
2.16%
Pledged Shares
0
Institutional Holding
24.84%
ROCE (avg)
20.58%
ROE (avg)
15.98%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
47
Industry P/E
37
Price to Book Value
6.26
EV to EBIT
36.23
EV to EBITDA
27.78
EV to Capital Employed
5.16
EV to Sales
7.21
PEG Ratio
3.53
Dividend Yield
0.04%
ROCE (Latest)
13.26%
ROE (Latest)
12.39%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company
OPERATING CF(Y)

Highest at Rs 2,751.99 Cr

OPERATING PROFIT TO INTEREST(Q)

Highest at 9.60 times

PAT(Latest six months)

At Rs 1,142.07 cr has Grown at 32.38%

PBT LESS OI(Q)

Highest at Rs 724.45 cr.

DPS(Y)

Highest at Rs 1.00

DPR(Y)

Highest at 2.03%

NET SALES(Q)

Highest at Rs 4,030.59 cr

PBDIT(Q)

Highest at Rs 1,056.19 cr.

EPS(Q)

Highest at Rs 13.75

-2What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 482.77 cr

Loading Valuation Snapshot...

Here's what is working for Mankind Pharma

Operating Profit to Interest - Quarterly
Highest at 9.60 times and Grown
each quarter in the last five quarters
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Cash Flow - Annually
Highest at Rs 2,751.99 Cr and Grown
each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 724.45 cr. and Grown
each quarter in the last five quarters
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Latest six months
At Rs 1,142.07 cr has Grown at 32.38%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Net Sales - Quarterly
Highest at Rs 4,030.59 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 1,056.19 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 724.45 cr has Grown at 37.8% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 525.91 Cr
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 13.75
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Dividend per Share (DPS) - Annually
Highest at Rs 1.00
in the last five years
MOJO Watch
Company is distributing higher dividend from profits generated

DPS (Rs)

Dividend Payout Ratio (DPR) - Annually
Highest at 2.03%
in the last five years
MOJO Watch
Company is distributing higher proportion of profits generated as dividend

DPR (%)

Here's what is not working for Mankind Pharma

Cash and Cash Equivalents - Half Yearly
Lowest at Rs 482.77 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents